Chiusura precedente | 15,00 |
Aperto | 14,99 |
Denaro | 0,00 x 45100 |
Lettera | 0,00 x 45100 |
Min-Max giorno | 14,99 - 15,00 |
Intervallo di 52 settimane | 3,07 - 15,00 |
Volume | |
Media Volume | 474.334 |
Capitalizzazione | 521,446M |
Beta (5 anni mensile) | 0,98 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -1,66 |
Prossima data utili | 03 mag 2023 - 08 mag 2023 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 15,00 |
AVEO to Become the U.S. Foundation for LG Chem Life Sciences’ Oncology DivisionSEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, in an all-cash transaction with an implied equity value of $571M on a ful
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders (the “Special Meeting”) held today, AVEO stockholders approved the adoption of the Agreement and Plan of Merger among LG Chem, Ltd. (“LG Chem”), a subsidiary of LG Chem and AVEO (the “merger agreement”). As previously
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend that AVEO Stockholders Vote “FOR” the TransactionBOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO’s Special Meeting of Stockholders (the “Special Meeting”) “FOR” the adoption of the Agreement and P